Skip to contentK
Kyntra Bio, Inc.
K
KYNBKyntra Bio, Inc. Q1 2023 · 10-Q
Revenue$36.16M$36.16M−40.6% vs Q1 2022 Net Income-$76.71M-$76.71MN/M vs Q1 2022 EPS Diluted-$0.81-$0.81N/M vs Q1 2022 Operating Income-$76,091,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
Free Cash Flowderived-$102,182,000N/M Margins · derivedOperating margin-210.4%−106.9 pt vs Q1 2022
Net margin-212.1%−108.2 pt vs Q1 2022
ended Mar 31, 2023 · filed May 8, 2023 · 38 d after period end